SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

November 10, 2014 07:00 ET

CTD Holdings Names Dr. Sharon H. Hrynkow to Scientific Advisory Board

Dr. Hrynkow Has Led Health and Policy Efforts at NIH, State Department, Global Virus Network and Other Agencies

ALACHUA, FL--(Marketwired - November 10, 2014) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that distribute and manufacture cyclodextrin-based products, including the orphan drug designated Trappsol® Cyclo™, today announced the appointment of Sharon H. Hrynkow, Ph.D., to the company's new Scientific Advisory Board. Dr. Hrynkow, who is the board's inaugural member and a developmental neuroscientist by training, has extensive experience leading global health programs and policy efforts at federal and non-profit agencies such as the National Institutes of Health (NIH), the U.S. State Department, and the Global Virus Network. 

Dr. Hrynkow was the long-serving Deputy Director of the John E. Fogarty International Center, the lead international organization within NIH that supports global health research and training; and a senior advisor and senior scientist at the State Department, where she advanced global health initiatives and partnerships. She is currently President of Global Virus Network, a non-profit that links top medical virology institutions around the world to research viral diseases and prevent them from spreading. Dr. Hrynkow is also Founder and Managing Partner of Global Health Consulting LLC, an organization that connects private sector groups, government representatives, and individuals from the U.S. and around the world to advance global health research and training. She holds a Ph.D. in Biomedical Science/Neuroscience from the University of Connecticut.

Dr. Hrynkow has received numerous honors for her contributions in health and life science, including the U.S. President's Rand Award for Meritorious Senior Executive for outstanding leadership in global health and scientific capacity building, and the King of Norway's Order of Merit Award for building life science collaboration between the U.S. and Norway.

It is through her role at Global Health Consulting that Dr. Hrynkow will advise CTD on potential new applications and market opportunities for Trappsol Cyclo. The product is currently used to treat Niemann Pick Type C, a rare and fatal disease in children that is caused by a genetic defect that prevents the body's cells from properly handling cholesterol.

"CTD's treatment for such a tragic global disease is truly groundbreaking," Dr. Hrynkow said. "I look forward to helping CTD identify other diseases that Trappsol Cyclo can treat, and providing guidance on new paths forward for the business."

Said Dr. Jeffrey Tate, President and CEO of CTD: "I am honored that Dr. Hrynkow has joined our Scientific Advisory Board. The breadth and depth of her experience combating global diseases is unparalleled, and her leadership will be invaluable."

About the Company: 
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: and

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information